These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 26198336)

  • 21. HBeAg-positive chronic hepatitis B: why do I treat my patients with pegylated interferon?
    Kao JH
    Liver Int; 2014 Feb; 34 Suppl 1():112-9. PubMed ID: 24373087
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sequential therapy with entecavir and PEG-INF in patients affected by chronic hepatitis B and high levels of HBV-DNA with non-D genotypes.
    Boglione L; D'Avolio A; Cariti G; Milia MG; Simiele M; De Nicolò A; Ghisetti V; Di Perri G
    J Viral Hepat; 2013 Apr; 20(4):e11-9. PubMed ID: 23490378
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hepatitis B viral kinetics: a dynamic puzzle still to be resolved.
    Neumann AU
    Hepatology; 2005 Aug; 42(2):249-54. PubMed ID: 16025494
    [No Abstract]   [Full Text] [Related]  

  • 24. Renal function during treatment with adefovir plus peginterferon alfa-2a vs either drug alone in hepatitis B/D co-infection.
    Mederacke I; Yurdaydin C; Großhennig A; Erhardt A; Cakaloglu Y; Yalcin K; Gurel S; Zeuzem S; Zachou K; Chatzikyrkou C; Bozkaya H; Dalekos GN; Manns MP; Wedemeyer H;
    J Viral Hepat; 2012 Jun; 19(6):387-95. PubMed ID: 22571900
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A randomized controlled trial of pegylated interferon-alpha2a plus adefovir dipivoxil for hepatitis B e antigen-negative chronic hepatitis B.
    Piccolo P; Lenci I; Demelia L; Bandiera F; Piras MR; Antonucci G; Nosotti L; Mari T; De Santis A; Ponti ML; Sorbello O; Iacomi F; Angelico M
    Antivir Ther; 2009; 14(8):1165-74. PubMed ID: 20032546
    [TBL] [Abstract][Full Text] [Related]  

  • 26. HBeAg-negative chronic hepatitis B: why do I treat my patients with pegylated interferon-alfa?
    Vlachogiannakos J; Papatheodoridis GV
    Liver Int; 2014 Feb; 34 Suppl 1():127-32. PubMed ID: 24373089
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Does the addition of lamivudine to peginterferon alpha-2a sustain response rates in HBeAg-negative hepatitis B?
    Cooksley G
    Nat Clin Pract Gastroenterol Hepatol; 2005 Jan; 2(1):12-3. PubMed ID: 16265091
    [No Abstract]   [Full Text] [Related]  

  • 28. A randomized controlled trial of sequential pegylated interferon-α and telbivudine or vice versa for 48 weeks in hepatitis B e antigen-negative chronic hepatitis B.
    Piccolo P; Lenci I; di Paolo D; Demelia L; Sorbello O; Nosotti L; Angelico M
    Antivir Ther; 2013; 18(1):57-64. PubMed ID: 22872648
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Therapy of hepatitis B virus infection].
    Trautwein C
    Praxis (Bern 1994); 2006 Sep; 95(36):1389-97. PubMed ID: 16989182
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treatment of patients with chronic hepatitis B who have failed previous antiviral treatment with pegylated interferon alpha2a (40 kda; PEGASYS).
    Chan HL; Wong VW; Chim AM; Wong GL; Chan HY; Sung JJ
    Antivir Ther; 2008; 13(4):555-62. PubMed ID: 18672534
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Durable hepatitis B surface antigen decline in hepatitis B e antigen-positive chronic hepatitis B patients treated with pegylated interferon-α2b: relation to response and HBV genotype.
    Sonneveld MJ; Rijckborst V; Cakaloglu Y; Simon K; Heathcote EJ; Tabak F; Mach T; Boucher CA; Hansen BE; Zeuzem S; Janssen HL
    Antivir Ther; 2012; 17(1):9-17. PubMed ID: 22267464
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Early hepatitis B virus DNA suppression can predict virologic response to peginterferon and lamivudine treatment.
    Chan HL; Wong VW; Wong GL; Chim AM; Chan HY; Sung JJ
    Clin Gastroenterol Hepatol; 2008 Sep; 6(9):1022-6. PubMed ID: 18585971
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Complete cure of HBV-HDV co-infection after 24weeks of combination therapy with pegylated interferon and ribavirin in a patient co-infected with HBV/HCV/HDV/HIV.
    Gozlan J; Lacombe K; Gault E; Raguin G; Girard PM
    J Hepatol; 2009 Feb; 50(2):432-4. PubMed ID: 19070927
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A multiphase model of the dynamics of HBV infection in HBeAg-negative patients during pegylated interferon-alpha2a, lamivudine and combination therapy.
    Colombatto P; Civitano L; Bizzarri R; Oliveri F; Choudhury S; Gieschke R; Bonino F; Brunetto MR;
    Antivir Ther; 2006; 11(2):197-212. PubMed ID: 16640101
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Adding pegylated interferon to a current nucleos(t)ide therapy leads to HBsAg seroconversion in a subgroup of patients with chronic hepatitis B.
    Kittner JM; Sprinzl MF; Grambihler A; Weinmann A; Schattenberg JM; Galle PR; Schuchmann M
    J Clin Virol; 2012 May; 54(1):93-5. PubMed ID: 22365367
    [TBL] [Abstract][Full Text] [Related]  

  • 36. HBeAg-positive chronic hepatitis B: why do i treat my patients with Nucleos(t)ide analogs?
    Buti M
    Liver Int; 2014 Feb; 34 Suppl 1():108-11. PubMed ID: 24373086
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Clinical analysis of seroconversion of HBsAg in chronic hepatitis B patients treated with PegIFN alpha-2a].
    Yang F; Wu XF; Li XH; Wei N
    Zhonghua Gan Zang Bing Za Zhi; 2009 Dec; 17(12):950-1. PubMed ID: 20038343
    [No Abstract]   [Full Text] [Related]  

  • 38. Effect of switching from treatment with nucleos(t)ide analogs to pegylated interferon α-2a on virological and serological responses in chronic hepatitis B patients.
    He LT; Ye XG; Zhou XY
    World J Gastroenterol; 2016 Dec; 22(46):10210-10218. PubMed ID: 28028369
    [TBL] [Abstract][Full Text] [Related]  

  • 39. HBeAg-positive chronic hepatitis B patients with prior long-time exposure to nucleos(t)ide analogues: "switch-to" or "add-on" PegIFN alfa, that is the question.
    Chen S; Zhang W
    J Hepatol; 2015 Jan; 62(1):239. PubMed ID: 25308178
    [No Abstract]   [Full Text] [Related]  

  • 40. Impact of occult hepatitis B virus infection or hepatitis B virus DNA integration on efficacy of chronic hepatitis C treatment with peginterferon and ribavirin: where are we?
    Hu KQ; Zhang YY
    J Clin Gastroenterol; 2014 Jan; 48(1):3-5. PubMed ID: 24045272
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.